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no metastasis can be detected by conventional clinical
or pathologic examinations.1-9 Importantly, some recent
studies have also reported worse postoperative out-
comes of such patients, with a trend toward recurrence
after curative operations.1,6-9 All of these findings have
made us envisage that the microscopic spread of cancer
cells to various distant organs is not merely an entrap-
ment of cancer cells but rather might be a metastasis or
an ongoing premanifestation state of occult disease. It is
imperative to elucidate the clinical and biologic behav-
ior of the microdissemination of cancer cells before tak-
ing some step to improve outcomes of patients with
lung cancer with a curative resection at early stages. In
this study, we performed immunohistochemistry for
cytokeratin fragments and examined the microdissemi-
nation of tumor cells in the lymph nodes of patients
with lung cancer with resections for cure whose dis-
eases had been diagnosed as stage I according to the
conventional pathologic examination. Furthermore, for
the possible molecular markers that may pertain to the
W ith the technologic breakthrough for the detectionof specific biologic markers for cancer cells, it has
been found that tumor cells are present in some distant
organs (such as lymph nodes, bone marrow, and periph-
eral blood circulation) in a significant proportion of var-
ious patients with cancer, including lung cancer, even if
Objective: We examined a microdissemination of cancer cells in lymph
nodes and assessed its clinical and biologic characteristics. 
Methods: Both primary tumors and lymph nodes (2030 nodes) were obtained
from 122 patients with primary stage I lung cancer who underwent curative
operations with routine systematic nodal dissection of both the hilar and the
mediastinal nodes. Immunohistochemical anticytokeratin staining was used
to detect nodal microdissemination of cancer cells. Vascular endothelial
growth factor, vascular endothelial growth factor type C, and nm23 expres-
sion at primary sites were also immunohistochemically studied. 
Results: In total, 35 patients (29%) had cytokeratin-positive cells in lymph
nodes. Increased expression of vascular endothelial growth factor (P =
.0001) and vascular endothelial growth factor type C (P < .0001) at primary
sites were significantly associated with nodal microdissemination, and nm23
was inversely correlated with microdissemination (P = .008). The 3- and 5-
year survivals for the patients with nodal microdissemination were 57% and
54%, respectively, which was a significantly worse prognosis as compared
with those prognoses (83% and 76%) for the patients without nodal
microdissemination (P = .006). The independent prognostic impact of nodal
microdissemination was not clear; however, vascular endothelial growth fac-
tor retained independent significance. 
Conclusion: All of these findings lead us to conclude that the microspread of
tumor cells in nodes detected by immunohistochemical anticytokeratin stain-
ing is definitely a metastasis with a high risk of systemic disease. (J Thorac
Cardiovasc Surg 2000;119:804-13)
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INCREASED VASCULAR ENDOTHELIAL GROWTH FACTOR AND VASCULAR ENDOTHELIAL GROWTH
FACTOR–C AND DECREASED NM23 EXPRESSION ASSOCIATED WITH MICRODISSEMINATION IN
THE LYMPH NODES IN STAGE I NON–SMALL CELL LUNG CANCER
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development of nodal microdissemination, we also
examined the expression of vascular endothelial growth
factor (VEGF), VEGF type C (VEGF-C), and nm23 in
primary tumor cells.
Patients and methods
Patients. Both primary tumor and lymph node samples
(2030 nodes) were obtained from 122 patients with primary
lung cancer in stage I who received curative operations with
routine systematic nodal dissection of both the hilar and the
mediastinal lymph nodes as previously described10,11 in
Kanazawa University Hospital from 1988 to 1991. The patho-
logic stage was classified according to the Japanese Lung
Cancer Society classification. The 78 men and 44 women had
a mean age of 65 ± 8.2 years (range, 46-84 years). The patho-
logic types were 77 adenocarcinomas, 37 squamous cell car-
cinomas, 6 adenosquamous carcinomas, 1 large cell carcino-
ma, and 1 mucoepidermoid carcinoma. According to TNM
classification, 78 patients had stage T1 N0 M0 disease and 44
patients, T2 N0 M0 disease. The basic clinical features of the
patients are summarized in Table I.
Immunohistochemistry for the detection of nodal
microdissemination of cancer cells. To examine the micro-
dissemination of cancer cells in lymph nodes, we performed
an immunohistochemical staining using a anticytokeratin
antibody, AE1/AE3 (Dako Corporation, Carpinteria, Calif).
After reviewing the hematoxylin and eosin–stained slides of
the primary tumors, we used invasive edge sections for the
paraffin-embedded tissues. For the paraffin-embedded
lymph node samples, we also reviewed the hematoxylin and
eosin–stained sections and confirmed that there was no
detectable nodal metastasis. The consecutive paraffin-
embedded lymph node and primary tumor tissue samples
were sectioned into 4 µm and were floated onto silanized
slides. Then the paraffin was removed from the sections
with xylene, and the sections were dehydrated with 98%
ethyl alcohol at 37°C. All tissue sections were boiled for 5
minutes in a 0.01 mmol sodium citrate solution (pH 6.0) in
a microwave oven 3 times and cooled and washed in phos-
phate-buffered saline solution (PBS). Endogenous peroxi-
dase was blocked by treatment with 0.3% hydrogen perox-
ide in methanol for 15 minutes, and specimens were washed
with PBS. These sections were incubated with normal goat
serum diluted 10-fold with PBS for 15 minutes at room tem-
perature for blocking. After being washed with PBS, the
sections were reacted with anti-AE1/AE3 antibody (diluted
50-fold with PBS) for 1 hour at room temperature. They
were then washed with PBS and reacted with biotin-labeled
goat anti-mouse immunoglobulin (Dako) for 2 hours. After
they were washed with PBS, avidin-biotin-peroxidase com-
plex was added and color was developed by 3-3´
diaminobenzidine (Sigma Chemical Company, St Louis,
Mo) with 0.03% hydrogen peroxide. Counterstaining was
done with hematoxylin and eosin. The negative control used
all reagents except for the primary antibody. Taken into
consideration together (the morphologic features such as
nuclear size, the nucleus-cytoplasmic ratio, and nucleola-
tion), cells that reacted with anticytokeratin antibody were
considered positive. The evaluation of the positivity was
determined by two independent viewers (Y.O. and H.N.)
without knowledge of the clinicopathologic factors.
In the few cases with discrepant evaluation, re-evaluation
was done on a second occasion after a consultation with the
other viewer, and agreement was reached.
Immunohistochemical assessment of biologic markers,
VEGF, VEGF-C, and nm23, in primary sites. We used
consecutive paraffin sections of the invasive edge of the pri-
mary tumors that were used for anticytokeratin staining and
stained immunohistochemically by the labeled streptavidin-
biotin method as described earlier.
The primary antibodies that were used were the anti-VEGF
polyclonal antibody (Santa Cruz Biotechnology Inc,
Heidelberg, Germany) diluted 100-fold, the anti-VEGF-C
polyclonal antibody (Santa Cruz Biotechnology Inc) diluted
100-fold, and the anti-nm23 monoclonal antibody (Dako)
diluted 50-fold. They were reacted for 2 hours at room tem-
perature. The second antibodies used were the biotin-labeled
goat anti-mouse immunoglobulin (Dako) for VEGF and
nm23 and biotin-labeled rabbit anti-goat immunoglobulin
(Dako) diluted 500-fold for VEGF-C.
For the assessment of VEGF-C staining, it was considered
positive staining when more than 10% of the tumor area was
stained. The immunoreactivities for VEGF were graded as
(-), (+), and (++), according to the staining intensity of the
tumor cells: (-) represents zero or less than 10% of positive
staining area, (+) represents 10% to 50% of positive staining
area, and (++) represents the strongest stain of more than
50% of positive staining area. In this study, we defined a
Table I. Clinical findings of the 122 patients with
lung cancer in stage I
Nodal microdissemination
Total Positive (%) Negative (%)
Patients (n) 122 35 (29) 87 (71)
Sex (n)
Male 78 22 56
Female 44 13 31
Mean age (y) 65.2 ± 8.2 65.5 ± 8.8 65.1 ± 8.0
Histologic features (n)
Adenocarcinoma 77 20 (26) 57 (74)
Squamous cell 37 14 (37) 23 (62)
carcinoma
Adenosquamous 6 0 6 (100)
carcinoma
Others 2 1 (50) 1 (50)
T factor (n)
T1 78 20 (26) 58 (74)
T2 44 15 (34) 29 (66)
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tumor with the strongest stain as VEGF overexpressing.12 For
the assessment of nm23 protein expression, tumors were con-
sidered positive if all the epithelial cells in the lesion showed
cytoplasmic staining. If any of the epithelial cells were
unstained, they were considered negative.13
Statistics. The association between other different vari-
ables was analyzed by the χ2 test. Nodal microdissemination,
age (≥66 vs <66 years), sex, T-factor, blood vessel invasion,
lymphatic vessel invasion, pathologic types (adenocarcinoma
vs squamous cell carcinoma), VEGF (strongest stain vs oth-
ers), VEGF-C (positive vs negative), and nm23 (positive vs
negative) were included in the assessment of prognostic indi-
cators. Age was classified as high or low relative to the medi-
an value in total patients in the group. Survival curves were
obtained by the Kaplan-Meier method and were compared
univariately by the log-rank test. Both univariate and multi-
variate analyses were performed with the Cox proportional
hazard model. The mean values were shown with ± standard
deviation.
Results
The detection of cytokeratin positive cells in
lymph nodes. A strong staining for AE1/AE3 was
found in all normal epithelial cells and tumor cells in
primary sites despite pathologic types. In total, among
122 patients with stage I lung cancer, 35 patients (29%)
had microdissemination of tumor cells within the
lymph nodes. As to the number of lymph nodes, 102 of
2030 nodes (5%) had cytokeratin positive cells that
were mainly identified at the edge portion of the nodes
(Fig 1) and sometimes located in vessels within the
nodes. If stratified by pathologic types, the percentage
of the patients with microscopic spread of tumor cells
was 26% (20/77 patients) in adenocarcinoma and 38%
(14/37 patients) in squamous cell carcinoma. There
were no significant differences in the percentage of the
patients with or without nodal microdissemination of
cancer cells according to age, sex, pathologic types
(adenocarcinoma vs squamous cell carcinoma), and T
factor (T1 vs T2; Table I).
Nodal microdissemination and vessel invasion.
From the pathologic point of view in primary sites, the
percentage of tumors with lymphatic vessel invasion
(60%) tended to be higher in patients with nodal
microdissemination compared with those patients with-
out nodal microdissemination (39.5%; P = .05). The
association between nodal microdissemination and blood
vessel invasion was no higher than expected by chance
(53.3% for positive microdissemination group and 42.0%
for negative microdissemination group; P = .3).
The expression of VEGF, VEGF-C, and nm23 in
primary sites, and their association with nodal
microdissemination of cancer cells. VEGF and
VEGF-C antigens were mainly identified in the cyto-
plasm of tumor cells and the endothelial cells of ves-
sels. Nm23 staining was found in the epithelial compo-
nent and was mainly cytoplasmic in tumor cells. The
examples of staining in tumor cells are shown in Fig 2.
The overall expression rates of VEGF and VEGF-C
were 80.3% (98/122 patients) and 45.1% (55/122
patients), respectively. Although VEGF antigen was
Fig 1. Photomicrographs of the consecutive sections of the lymph node with microspread of cytokeratin positive
cells. Immunohistochemical staining was done using anti-AE1/AE3 antibody. Scale bar indicates 20 µm.
(Original magnification, × 400.)
Fig 2. Immunohistochemical staining for VEGF (A), VEGF-C (B), and nm23 (C). VEGF and VEGF-C antigens
were mainly identified in the cytoplasm of tumor cells in addition to the endothelial cells of vessels. Nm23 staining
was found in the epithelial component and was mainly cytoplasmic in tumor cells. (Original magnifications, ×400.)
A
B
C
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detected in large amounts in both tumor groups, those
with nodal microdissemination (88.6%) and those
without microdissemination (77.0%; P = .15), the per-
centage of patients with the strongest VEGF stain were
68.6% (24/35 patients) in tumors with nodal microdis-
semination and only 31.0% (27/87 patients) in those
patients without nodal microdissemination (P = .0001).
The percentage of VEGF-C–positive tumors with nodal
microdissemination (74.3%) was significantly higher
than that without it (33.3%; P < .0001). On the other
hand, nm23 expression was inversely correlated with
nodal microdissemination (P = .008). Table II gives an
overview of the results.
Univariate and multivariate analyses of clinico-
pathologic and biologic characteristics. The 3- and
5-year survivals for the patients with nodal microdis-
semination (n = 35 patients) were 57.1% and 54.3%,
respectively, having a significantly worse prognosis as
compared with those for the patients without nodal
microdissemination (n = 87 patients; 82.8% and
75.9%, respectively; P = .006; Fig 3). In univariate
analysis, older age (P = .03), T2 factor (P < .0001),
lymphatic vessel invasion (P = .003), blood vessel inva-
sion (P = .005), overexpression of VEGF (P = .0015),
and nm23 negativity (P = .0007) were significantly
associated with poor survival, besides the nodal
microdissemination. Among various clinical parame-
ters, sex (male) also tended to be relevant to poor sur-
vival (P = .05; Table III). As a result of multivariate
analysis, VEGF expression and the T factor were char-
acteristics that retained a significant independent prog-
nostic impact on overall survivals (Table IV).
If stratified by nodal status, the results of univariate
analysis showed that VEGF (P = .034), nm23 (P = .048),
and T factor (P = .029) were significant prognostic indi-
cators in the positive nodal microdissemination group (n
= 35 patients; Table III). VEGF remained a significant
independent prognostic indicator in the group of patients
Table II. VEGF, VEGF-C, and nm23 expression in tumors
VEGF expression VEGF-C expression nm23 expression
Nodal Positive stain* Strongest stain† Positive stain‡ Positive stain§
microdissemination (%) P value (%) P value (%) P value (%) P value
Positive 89 .15 69 .0001 74 <.0001 20 .008
Negative 77 31 33 46
TOTAL 80 42 45 38
Note: The association between different variables was analyzed by the χ2 test.
*>10% of positive staining area in tumor cells.
†>50% of positive staining area in tumor cells.
‡>10% of positive staining area in tumor cells.
§Defined as positive if all the epithelial cells in tumors showed diffuse cytoplasmic staining.
Fig 3. Kaplan-Meier survival plots for stage I lung cancers subdivided according to the nodal microspread (MD)
of cytokeratin positive cells. The difference in survival between the positive nodal microspread group (n = 35
patients) and negative nodal microspread group (n = 87 patients) was significant (P = .006).
} } } }
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with nodal microdissemination (Table V). Among the
patients with nodal microdissemination, the survival of
the patients with VEGF overexpression (n = 24) was sig-
nificantly worse than that of the patients without VEGF
overexpression (n= 11, P < .05) (Fig 4).
The extent of lymph nodes with cytokeratin posi-
tive cells and the revised staging. Among 35 patients
with nodal microdissemination, 7 patients had N1 dis-
ease and 28 patients had N2 disease, according to the
sites of affected lymph nodes. Cytokeratin-positive
tumor cells were found in 1 nodal station in 26 patients
and in multiple nodes in 9 patients. Affected nodes
were restricted to the regional lymph nodes in 17
patients; however, those outside the regional lymph
nodes were involved in 11 patients. If the primary
tumor was located in an upper lobe, cytokeratin-posi-
tive cells were mainly detected in the upper mediastinal
area (12/14 patients). In patients with the primary
tumor in the left lower lobe, cytokeratin-positive cells
were mainly detected in the lower mediastinal area (3/4
patients). In tumors in the right lower lobe, however,
the dominant affected area was the upper mediastinum
(7/8 patients; Fig 5). After revised staging based on the
nodal microdissemination, patients with N1 and N2
diseases showed significantly poorer survival than
those with N0 (P = .05 and P = .01, respectively; Table
VI).
Discussion
The percentage of patients with positive cytokeratin
cells within lymph nodes differs from study to study,
partly because of the difference of the anticytokeratin
antibody used. In patients with lung cancer whose disease
was diagnosed as N0 according to the conventional
Table IV. Cox proportional hazard regression analysis with 122 patients who had stage I lung cancer
Characteristics
Factors Unfavorable Favorable P value Hazard ratio (95% CI)
VEGF* Strongest Others .02 2.3 (1.16-4.7)
T factor T2 T1 .006 3.3 (0.1-0.7)
Nodal microdissemination Positive Negative .15 1.69 (0.83-3.47)
nm23 Negative Positive .18 0.53 (0.20-1.4)
Blood vessel invasion Positive Negative .3 2.1 (0.58-8.0)
Age (y) ≥66 <66 .7 0.88 (0.42-1.84)
Sex Male Female .8 1.13 (0.50-2.54)
Lymphatic vessel invasion Positive Negative .9 0.96 (0.25-3.8)
*A tumor was included in VEGF high-expressing group if positive staining area in tumor cells was more than 50%.
Table III. Prognostic impact of clinicopathologic and biologic factors on overall survival (univariate analysis)
Nodal microdissemination
Total Positive (n = 35) Negative (n = 87)
Hazard ratio Hazard ratio Hazard ratio 
Factors P value (95% CI) P value (95% CI) P value (95% CI)
Age (≥ 66 vs <66 y) .03 1.94 (1.03-3.6) .09 2.3 (0.85-6.1) .2 1.66 (0.73-3.8)
Sex (male vs female) .05 1.98 (0.97-4.0) .5 1.43 (0.54-3.8) .04 2.9 (1.00-8.7)
Pathologic type .6 0.78 (0.39-1.55) .6 0.78 (0.30-1.98) .98 0.99 (0.35-2.8)
(adeno vs squamous)
T factor (T1 vs T2) <.0001 3.9 (2.0-7.4) .03 2.7 (1.06-7.1) .0001 4.6 (1.95-10.9)
Lymphatic vessel invasion .003 2.6 (1.35-5.2) .6 1.3 (0.47-3.59) .004 3.5 (1.41-8.71)
(positive vs negative)
Blood vessel invasion .005 2.1 (0.49-9.3) .3 1.7 (0.62-4.68) .01 2.92 (1.24-6.89)
(positive vs negative)
VEGF (strongest vs others)* .002 2.6 (1.4-4.9) .03 3.5 (1.00-12) .2 1.7 (0.73-3.9)
VEGF-C (positive vs negative) .4 1.34 (0.58-3.1) .2 0.55 (0.2-1.4) .4 1.43 (0.62-3.3)
nm23 (positive vs negative) .0007 3.7 (1.64-8.4) .05 5.9 (0.78-45) .03 2.7 (1.06-6.9)
Nodal micro-dissemination .006 2.4 (1.31-4.5)
(positive vs negative)
HR, Hazard ratio.
*A tumor was included in VEGF high expressing group if positive staining area in tumor cells was more than 50%.
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pathologic findings, a wide spectrum of the percentage of
nodal microdissemination of cytokeratin-positive cells
has been reported (10.4%-70%).5,9,14,15 The anticytoker-
atin antibody used in this study is a mixture of anti-AE1
monoclonal antibody that recognizes various keratins of
the acidic subfamily and anti-AE3 antibody that recog-
nizes the basic keratins of various molecular weights.
Therefore it is a pan-specific cocktail of the monoclonal
antibodies for human cytokeratins. As a result of using
this antibody, we found that 29% (35/122 patients) of the
patients with stage I lung cancer had nodal microdissem-
ination of cytokeratin-positive tumor cells.
In this study, we highlighted two angiogenesis-asso-
ciated factors, VEGF and VEGF-C, and the metastasis
associated factor, nm23, for the possible markers that
pertain to the formation of nodal micrometastasis. As
a result, we clearly found that the increased expres-
sion of VEGF and VEGF-C were significantly associ-
ated with nodal microdissemination of tumor cells
together with the inhibitory expression of nm23. For
the connection of VEGF expression with lymph node
metastasis, we previously reported that VEGF gene
expression at primary sites was greater in patients
with lung cancer with nodal involvement than in those
patients without nodal metastasis.16 We also found
that VEGF expression levels in metastatic lymph
nodes themselves were conspicuously higher than
those in the primary site.16 Regarding VEGF function
Table V. Cox proportional hazard regression analysis in patients with stage I lung cancer with or without nodal
microdissemination of tumor cells
Characteristics
Unfavorable Favorable P value Hazard ratio (95% CI)
Factors in positive nodal 
microdissemination group (n = 35)
VEGF* Strongest Others .007 3.5 (1.41-8.8)
T factor T2 T1 .014 3.2 (0.12-0.79)
nm23 Negative Positive .69 1.22 (0.45-3.3)
Factors in negative nodal 
microdissemination group (n = 87)
T factor T2 T1 .02 3.3 (1.21-9.1)
Sex Male Female .2 2.2 (0.62-7.6)
Lymphatic vessel invasion Positive Negative .4 5.18 (0.157-171)
nm23 Negative Positive .4 1.58 (0.56-4.4)
Blood vessel invasion Positive Negative .7 0.51 (0.016-16.5)
*A tumor was included in VEGF high expressing group if positive staining area in tumor cells was more than 50%.
Fig 4. Kaplan-Meier survival plots for stage I lung cancers subdivided according to the nodal microdissemina-
tion (MD) and VEGF expression level. A tumor was included in the VEGF high-expressing group if positive
staining area in tumor cells was more than 50%.
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that is different from angiogenesis, a recent report
actually revealed its potential role in allowing tumor
cells to avoid the host immune response.17
Furthermore, it has also been reported that the block-
ade of a VEGF receptor (the kinase insert domain-
containing receptor) induced suppression of cancer
invasion.18 According to the results, we consider that
cancer cells with high VEGF expression may elicit
some function for invasion and metastasis, and anoth-
er function that is different from the proliferation of
endothelial cells may affect the nodal metastasis.
The function of VEGF-C also appears to extend to
the lymphatic system as a ligand for fms-like tyrosine
kinase 4, which was originally found in lymphatic
endothelium.19,20 Although lymphangiogenesis within
tumors has not yet been documented, we previously
reported a significant relationship between VEGF-C
expression levels and microlymphatic vessel density
within resected malignant pleural tumors.21 In prostat-
ic carcinoma, it has recently been reported that
increased VEGF-C expression is associated with lymph
node metastasis.22 The fundamental role of VEGF-C as
a novel stimulator for vascular and/or lymphatic
endothelial cells needs to be further studied to elucidate
its connection with lymph node metastasis.
Nm23 is a putative antimetastatic gene, and its
inverse correlation with lymph node metastasis has
been reported by some researchers.23-25 Regarding two
human nm23 genes (nm23-H1 and -H2), a previous
report has shown that the reduced expression of both
genes was related to nodal involvement.23 In this study,
we used the antibody that recognized both of the nm23
Fig 5. Intramediastinal spread of cytokeratin-positive tumor cells related on sites of the primary tumor. RLL,
Right lower lobe; RML, right middle lobe; RUL, right upper lobe; LUL, left upper lobe; LLL, left lower lobe. ❍,
Single-level metastasis; , multilevel metastasis; the bars between the closed circles signify the same cases.
Table VI. Overall survival based on the revised staging, according to the nodal microdissemination in 122 patients
with stage I non–small cell lung cancer
Survival
Revised stage Patients (n) 3 y (95% CI) N 5 y (95% CI) N
Stage I (N0)*† 87 83 (75-91) 73 76 (67-85) 65
Stage II (N1)* 7 57 (20-94) 4 43 (6-80) 3
Stage IIIA (N2)† 28 57 (39-75) 16 57 (39-75) 16
The survival was obtained by the Kaplan-Meier method.
*P = .01. 
†P = .05 by the log-rank test.
are located in the right lower lobe, including the nonre-
gional area, meticulous lymph node dissection should
be needed.
In conclusion, the biologic and clinicopathologic
characteristics of the nodal microdissemination appear
to be valid for the concept that the presence of a small
amount of cancer cells in lymph nodes detected by anti-
cytokeratin staining is definitely a metastasis. It will be
worthwhile to embark on the next step to evaluate the
efficacy of selective postoperative adjuvant therapy for
affected patients to inhibit the manifestation of the
occult systemic disease. Although the efficacy of adju-
vant chemotherapy against the nodal micrometastasis is
not clear, in the patients with VEGF overexpression,
antiangiogenic strategies may also be a candidate.
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isotypes and found that the negativity of nm23 expres-
sion was associated with nodal microdissemination.
Among these three biologic markers that are associ-
ated with nodal microdissemination, VEGF and nm23
had a significant prognostic impact on overall survival.
VEGF also retained a significant impact as an indepen-
dent prognostic indicator together with T factor. As of
now, several studies reported a poor outcome for
patients with lung cancer with strong VEGF expres-
sion.26-30 In terms of the association of VEGF expres-
sion and relapse of the disease, we already confirmed
that tumors with recurrence significantly highly
expressed VEGF compared with those without recur-
rence in stage I patients with curative operations.12 In
this study, VEGF actually remains a significant inde-
pendent prognostic indicator both in the total and also
in the positive nodal microdissemination group. After
revised staging based on the sites of nodal microdis-
semination, patients with N1 or N2 microdissemination
showed significantly worse survival than those with
N0. There was not any difference in survival between
N1 and N2 microdissemination, probably because of
the small sample scale.
Because the presence of nodal involvement generally
has a decisive meaning for the outcome of patients with
lung cancer, the reason that VEGF-C did not have a sig-
nificant prognostic impact is not clear. Although the
VEGF-C expression was associated with nodal metas-
tasis, the gravity of its role may not be so great as that
of VEGF. Because the increased expression of VEGF is
a possible link to distant metastasis through new blood
vessels as a route of distant metastasis, increased
VEGF expression in tumors with nodal microdissemi-
nation may also represent a high risk of systemic dis-
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